LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | Seliciclib | 0.04 | uM | LJP5 | 3 | J06 | 72 | hr | 1476 | 4024 | 3694 | 1.0893 | 1.1488 |
SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 1 | O18 | 72 | hr | 1476 | 3003 | 3694 | 0.8129 | 0.6883 |
SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 2 | O18 | 72 | hr | 1476 | 3356 | 3694 | 0.9085 | 0.8475 |
SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 3 | O18 | 72 | hr | 1476 | 3181 | 3694 | 0.8611 | 0.7686 |
SK-BR-3 | XL147 | 0.04 | uM | LJP5 | 1 | G12 | 72 | hr | 1476 | 3992 | 3694 | 1.0807 | 1.1344 |
SK-BR-3 | XL147 | 0.04 | uM | LJP5 | 2 | G12 | 72 | hr | 1476 | 4302 | 3694 | 1.1646 | 1.2742 |
SK-BR-3 | XL147 | 0.04 | uM | LJP5 | 3 | G12 | 72 | hr | 1476 | 4398 | 3694 | 1.1906 | 1.3175 |
SK-BR-3 | Saracatinib | 0.04 | uM | LJP6 | 1 | D12 | 72 | hr | 1476 | 4380 | 3694 | 1.1857 | 1.3094 |
SK-BR-3 | Saracatinib | 0.04 | uM | LJP6 | 2 | D12 | 72 | hr | 1476 | 4019 | 3694 | 1.0880 | 1.1465 |
SK-BR-3 | Saracatinib | 0.04 | uM | LJP6 | 3 | D12 | 72 | hr | 1476 | 4300 | 3694 | 1.1640 | 1.2733 |
SK-BR-3 | Selumetinib | 0.04 | uM | LJP6 | 1 | M12 | 72 | hr | 1476 | 3894 | 3694 | 1.0541 | 1.0902 |
SK-BR-3 | Selumetinib | 0.04 | uM | LJP6 | 2 | M12 | 72 | hr | 1476 | 4148 | 3694 | 1.1229 | 1.2047 |
SK-BR-3 | Selumetinib | 0.04 | uM | LJP6 | 3 | M12 | 72 | hr | 1476 | 3860 | 3694 | 1.0449 | 1.0748 |
SK-BR-3 | Sirolimus | 0.04 | uM | LJP6 | 1 | L18 | 72 | hr | 1476 | 2090 | 3694 | 0.5658 | 0.2766 |
SK-BR-3 | Sirolimus | 0.04 | uM | LJP6 | 2 | L18 | 72 | hr | 1476 | 2657 | 3694 | 0.7193 | 0.5323 |
SK-BR-3 | Sirolimus | 0.04 | uM | LJP6 | 3 | L18 | 72 | hr | 1476 | 2652 | 3694 | 0.7179 | 0.5300 |
SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 1 | B12 | 72 | hr | 1476 | 3399 | 3694 | 0.9201 | 0.8669 |
SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 2 | B12 | 72 | hr | 1476 | 3344 | 3694 | 0.9052 | 0.8421 |
SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 3 | B12 | 72 | hr | 1476 | 3177 | 3694 | 0.8600 | 0.7668 |
SK-BR-3 | SU11274 | 0.04 | uM | LJP5 | 1 | J12 | 72 | hr | 1476 | 4513 | 3694 | 1.2217 | 1.3693 |
SK-BR-3 | SU11274 | 0.04 | uM | LJP5 | 2 | J12 | 72 | hr | 1476 | 4212 | 3694 | 1.1402 | 1.2336 |
SK-BR-3 | SU11274 | 0.04 | uM | LJP5 | 3 | J12 | 72 | hr | 1476 | 4287 | 3694 | 1.1605 | 1.2674 |
SK-BR-3 | Fedratinib | 0.04 | uM | LJP5 | 1 | L06 | 72 | hr | 1476 | 4034 | 3694 | 1.0920 | 1.1533 |
SK-BR-3 | Fedratinib | 0.04 | uM | LJP5 | 2 | L06 | 72 | hr | 1476 | 4308 | 3694 | 1.1662 | 1.2769 |
SK-BR-3 | Fedratinib | 0.04 | uM | LJP5 | 3 | L06 | 72 | hr | 1476 | 4137 | 3694 | 1.1199 | 1.1998 |